Science

Fatty liver disease may be five different conditions, Mayo Clinic study finds

Researchers grouped 4,600 patients into five subtypes. Some are driven by genes rather than weight, and may carry higher risk. The findings still need confirming.

Published

1 day ago

October 22, 2026

Massih Shahbazi

An ultrasound machine in a clinic, in black and white, beside the headline One disease, five kinds

Fatty liver disease is usually explained as one problem with one story: too much weight, too much sugar, a liver slowly choking on fat. A new study from the Mayo Clinic suggests that story only fits some of the people living with it.

Researchers say metabolic dysfunction-associated steatotic liver disease, or MASLD, the condition most people know as fatty liver disease, is actually made up of five distinct subtypes with different risks, according to a Mayo Clinic release published by ScienceDaily. The study was published in Nature Communications.

I read the release carefully, including what it doesn’t say. That second part matters here.

What the researchers did

The team analyzed genetic sequencing results and medical records from more than 4,600 patients with MASLD, according to the release. The data came from Mayo Clinic’s Research Data Atlas, which links genetic data to health records and draws on the Tapestry Study, a project with exome data from more than 100,000 participants.

Using what the release describes as “advanced computer models,” the researchers grouped patients with similar genetic and clinical features. They looked at liver enzymes, body mass index, blood fats and other conditions, including diabetes, depression and sleep apnea. Five groups emerged.

The first author is Tahmina Sultana Priya, with Shulan Tian and Eric Klee as co-senior authors, all at Mayo Clinic. Konstantinos Lazaridis, who led the Tapestry Study, is a co-author, and Virginia Tech collaborated on the work. Pairing genetic data with ordinary clinical records at this scale is what made it possible to see patterns that neither source would show on its own.

Not everyone fits the usual profile

Some of the subtypes are closely tied to obesity and diabetes, the familiar picture, the release said. Others appear to be driven more by inherited genetic differences.

That second finding is the striking one. The genetically driven subtypes were associated with a greater likelihood of progressing to advanced liver damage, even in people without the typical metabolic risk factors, according to the release. In other words, someone who doesn’t look like the textbook fatty liver patient may be among those at higher risk.

Across the subtypes, the researchers saw different associations with heart disease, liver failure, cancer and the need for a liver transplant. For the first time, particular subtypes were also linked to depression, sleep apnea and migraine, the release said.

Klee said the approach could help doctors “anticipate its course and intervene before the most serious damage occurs,” according to the release.

What the study did not show

The release doesn’t name the five subtypes or say which one carries which risk, so the most useful detail for patients isn’t public in the summary yet. The full paper should be the place to look.

The links to depression, sleep apnea and migraine are associations. They don’t show that fatty liver disease causes those conditions, or the other way around.

The findings also haven’t been confirmed elsewhere. The team plans to test them in larger and more diverse populations, according to the release. And the biggest practical question is still open: whether the subtypes respond differently to treatments, including GLP-1 drugs. The researchers say they still need to test that.

Why it matters

If the subtypes hold up, the payoff is earlier, more targeted care. Doctors might identify vulnerable patients sooner, screen more precisely and choose treatments based on the biology driving each person’s disease, according to the release.

That’s a meaningful shift for a condition often managed with general advice about diet, exercise and weight. Advice like that helps many people. But if some patients’ disease is driven mainly by their genes, telling them to lose weight may not address what’s actually damaging their liver.

From the patient’s chair

My read: the most important message here is for the people who get told their liver is fine because they don’t fit the profile. A patient without obesity or diabetes might be reassured too easily. This research suggests that, for some of them, the genetic risk could be the more dangerous one.

None of this changes what a doctor will tell you tomorrow. It’s a step toward a future where a liver diagnosis comes with a subtype, the way many cancers now do, and treatment follows from it.

What comes next

Validation in larger and more varied groups of patients, and tests of whether the subtypes respond differently to treatment, are the next steps the team describes. Until then, the five subtypes are a research map, not a clinical tool.

Fatty liver disease is often called silent. This study suggests it may also be several different conditions sharing one name.